about
Genetic and genomic analysis of hyperlipidemia, obesity and diabetes using (C57BL/6J × TALLYHO/JngJ) F2 mice.Fatty acid- and cholesterol transporter protein expression along the human intestinal tract.Effect of sitagliptin on lipid profile in patients with type 2 diabetes mellitus.Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial.Desaturation index versus isotopically measured de novo lipogenesis as an indicator of acute systemic lipogenesisDyslipidemia in young patients with type 1 diabetes mellitus.Exercise improved lipid metabolism and insulin sensitivity in rats fed a high-fat diet by regulating glucose transporter 4 (GLUT4) and musclin expression.Aberrant promoter methylation profile of Niemann-pick type C1 gene in cardiovascular diseaseEffect of breviscapine injection on clinical parameters in diabetic nephropathy: A meta-analysis of randomized controlled trials.Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans.Pharmacological inhibition of diacylglycerol acyltransferase-1 and insights into postprandial gut peptide secretion.The hypertriglyceridemia is associated with isolated impaired glucose tolerance in subjects without insulin resistance.Antidiabetic Activity of Extracts in Streptozotocin-Induced Diabetic Rats
P2860
Q33774706-C577F353-F7F8-4053-B634-29AA0DE96A9AQ33818527-02B3FAA5-2AED-4216-AF7D-BBECAE34D6FFQ34016283-4EFF8088-A289-49F0-B485-0F3A896AFE24Q34084495-A16B91BC-D932-475C-A414-A13F85F48B6DQ35132990-F51D2808-4460-4541-8404-F47956E8788BQ35685832-1DD34D41-D65D-4BCE-82D3-9A433DAFE41FQ36867550-0AA0980C-DFD4-46AB-AFC0-3E826714C76DQ36916212-1956CDFC-7220-4D79-AF4C-77DB368B3E10Q37204321-D2E0145D-4DC2-4C7D-89B8-F8DFC701935EQ37834033-17314584-FF7B-4286-93BF-CA0A3854A7CCQ38005223-4A2C188A-C254-47F1-A62F-C092126AF0EDQ42248942-15104874-D694-4932-BDED-DCC98B9BC604Q46680329-E3EBEE46-E9C2-4F69-B3D0-7786E070E633Q47156353-42D8E21D-00A2-4B34-8AB3-60DB86C18F4AQ51317539-696D6C6E-8025-4DC4-B3D2-E8D6134D1159Q58561524-13D8A3BA-0D36-493C-BA4F-27C3F643B1E3
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targets for intervention in dyslipidemia in diabetes.
@en
Targets for intervention in dyslipidemia in diabetes.
@nl
type
label
Targets for intervention in dyslipidemia in diabetes.
@en
Targets for intervention in dyslipidemia in diabetes.
@nl
prefLabel
Targets for intervention in dyslipidemia in diabetes.
@en
Targets for intervention in dyslipidemia in diabetes.
@nl
P356
P1433
P1476
Targets for intervention in dyslipidemia in diabetes.
@en
P2093
Gerald H Tomkin
P304
P356
10.2337/DC08-S260
P407
P478
31 Suppl 2
P577
2008-02-01T00:00:00Z